Piper Jaffray recently conducted a survey of hernia surgeons and received a strong feedback for LifeCell Corporation. The potential for LifeCell’s Strattice xenograft is expected to increase as surgeons place little importance on the source of material for the selection of biologic meshes. Piper Jaffray upgraded its rating from ‘Market Perform’ to ‘Outperform’ for the company and raised its price target to $54. The price target represents a P/E ratio of 39 as EPS is estimated to be $1.39.